Release: Nicotine-Based Drug May Help Athletes Build New Muscle Mass Faster, Eliminate The Need For Rigorous Dietary Regimens Or Dangerous Steroids, And Provide More Rapid Muscle Replacement To Stroke Victims

Endovasc Files USPTO Provisional Patent Application for Development of Muscle Mass Combining Exercise Training With ANGIOGENIX(TM)

MONTGOMERY, Texas, Aug. 8 /PRNewswire-FirstCall/ -- Endovasc Ltd., Inc. (OTC Bulletin Board: ENVC; Berlin: ED7) announced today the filing of a patent application for a novel method for stimulating the development of muscle mass by combining exercise training with nicotinic ANGIOGENIX(TM) or other nicotinic acetylcholine receptor (nAChR) agonist.

Endovasc is the company behind a revolutionary, nicotine-based ANGIOGENIX(TM) treatment that may grow new heart tissue. The treatment has been approved for Phase III FDA trials. Using Endovasc's treatment, test animals with an artificially-induced coronary artery constriction grew new blood vessels to replace the lost blood vessel supply to their hearts. In test animals at Stanford University, ANGIOGENIX(TM) (nAChR agonist) treated animals not only regained blood vessels in the blood-starved zones of leg muscle, but demonstrated a four-fold increase in the recruitment, migration and mobilization of stem cells and progenitor cells in the area. Some of the stem cells were capable of differentiating into muscle and cartilage.

Now Endovasc is developing experiments to demonstrate that ANGIOGENIX(TM) may cause these new cells to develop muscle mass and promote body fitness.

"Development of muscle mass and body fitness is a multi-billion dollar industry worldwide. Myriad nutriceutical supplements and pharmacological medicines are used to restore, augment and repair body tissues for both aesthetic and medical purposes. For example, stroke victims with muscle dystrophy require extensive rehabilitation of muscle use during recovery in order to restore muscle mass.

Fitness devotees and athletes seek to increase stamina, strength and muscle force to enhance personal appearance or performance. Our studies show that ANGIOGENIX(TM) can recruit undifferentiated progenitor cells and stem cells from the bone marrow, and cause these cells to migrate and mobilize to a specific area of the body. Some recent studies show that the body's own stem cells can engraft and become heart tissue. As far as we know we will be the first to study the body's ability to build new muscle mass using ANGIOGENIX(TM). This may be great news to stroke victims with atrophied muscle, athletes, and to anyone hoping to replace fat with muscle," says Dr. David P. Summers, Chief Executive Officer for Endovasc.

The benefits of using the body's own stem cells to replace, restore or augment body muscle without the arduous regimen are obvious. All traditional health regimens typically rely on the effects of strenuous exercise programs, supplemented with various nutritional diets. They all require a relentless conformity to rigorous regimens, are costly and time-consuming, and few result in any long-term success. That is why one of the common temptations for persons seeking to add muscle mass is the use of steroids, even though they have been proven to have considerable negative side effects, including liver and heart damage.

Endovasc's invention comprises a method of utilizing nicotine or other nicotinic acetylcholine receptor agonist to stimulate, recruit and mobilize new muscle cells to augment, strengthen or replace muscle cells in the body. The muscle cells may be differentiated from stem cells with mesenchymal linage, which may be endogenous or exogenous. The muscle cells are recruited to a specific area of the body by a training exercise. The exercise results in the muscle group exceeding the cell replenishing effects of a normal lifestyle. The exercise causes an abnormal physiologic response in the muscle group, thereby causing release of various biologic responses to further enhance the increase of tissue mass. Such a response causes the muscle cells to express nicotinic acetylcholine receptors. Nicotine or a nicotine acetylcholine receptor agonist such as ANGIOGENIX(TM) is used to bind the receptors. "The binding to the nicotinic acetylcholine receptors stimulates the release of growth factors, including vascular endothelial growth factors (VEGF), basic fibroblast growth factor (bFGF), with products of cyclooxygenase and nitric oxide pathway, and may include human growth factor HGH, other chemokines, cytokines and attractants to stem cell recruitment in the bone marrow. These cells may then migrate and mobilize at the target physiologic tissue or muscle groups. The stem cells then change into the phenotype and take on the characteristics of the target muscle group or physiologic tissues," said Summers.

About EndovascEndovasc Ltd., Inc. is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The Company's products and processes include: Liprostin(TM), ANGIOGENIX(TM) (Nicotine Receptor Agonist), PROStent(TM) stent-coating technology, and a biodegradable resorbable prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com . (Investor questions and requests for materials can be submitted online.)

Contact Information: Investor Relations, Endovasc Ltd., Inc., 15001 Walden Road, Ste. #108, Montgomery, TX 77356, Phone: +1-936-448-2222, Fax: +1-936-582-2250, InvestorRelations@endovasc.com.